IL-23抑制剂治疗克罗恩病的研究进展
Research Progress of IL-23 Inhibitors in the Treatment of Crohn’s Disease
DOI: 10.12677/acm.2026.1662192, PDF,   
作者: 周诗雨, 周旭春*：重庆医科大学附属第一医院消化内科，重庆
关键词: 克罗恩病；生物制剂；IL-23；安全性；治疗进展；Crohn’s Disease； Biologic Agents； IL-23； Safety； Therapeutic Progress
摘要: 克罗恩病(Crohn’s Disease, CD)是一种原因不明的慢性炎性肉芽肿性疾病，可累及全消化道，好发于末端回肠和结肠，其发病与生物遗传易感性、肠道微生物群、免疫系统失调等多因素相关。CD尚无法根治，治疗的主要目的是减轻炎症活动、维持缓解、降低复发率及手术率等；相对于5-氨基水杨酸类、激素和免疫抑制剂等传统药物，生物制剂因其更为明确的疗效和良好的安全性而成为目前主流治疗方法。其中靶向IL-23p19和IL-12/23p40抑制剂通过阻断关键促炎通路，从源头干预疾病进程，标志着CD治疗的重要里程碑。本综述系统阐述IL-23相关通路在CD发病中的机制，并总结不同IL-23抑制剂治疗CD的研究进展。
Abstract: Crohn’s disease (CD) is a chronic inflammatory granulomatous disorder of unknown etiology that can involve the entire digestive tract, with a predilection for the terminal ileum and colon. Its pathogenesis is associated with multiple factors including genetic susceptibility, gut microbiota, and immune dysregulation. Currently, CD remains incurable, and the primary goals of treatment are to reduce inflammatory activity, maintain remission, and lower relapse and surgical rates. Compared with conventional therapies such as 5-aminosalicylates, corticosteroids, and immunosuppressants, biologic agents have become the mainstream treatment due to their more definitive efficacy and favorable safety profiles. Among these, inhibitors targeting IL-23p19 and IL-12/23p40 interrupt key pro-inflammatory pathways, intervening in disease progression at the source, representing a significant milestone in CD treatment. This review systematically elucidates the mechanisms of IL-23-related pathways in CD pathogenesis and summarizes the research progress of different IL-23 inhibitors for CD treatment.
文章引用：周诗雨, 周旭春. IL-23抑制剂治疗克罗恩病的研究进展[J]. 临床医学进展, 2026, 16(6): 42-50. https://doi.org/10.12677/acm.2026.1662192

参考文献

[1] Kobayashi, M., Fitz, L., Ryan, M., Hewick, R.M., Clark, S.C., Chan, S., et al. (1989) Identification and Purification of Natural Killer Cell Stimulatory Factor (NKSF), a Cytokine with Multiple Biologic Effects on Human Lymphocytes. The Journal of experimental medicine, 170, 827-845. [Google Scholar] [CrossRef] [PubMed]
[2] Oppmann, B., Lesley, R., Blom, B., Timans, J.C., Xu, Y., Hunte, B., et al. (2000) Novel P19 Protein Engages Il-12p40 to Form a Cytokine, IL-23, with Biological Activities Similar as Well as Distinct from Il-12. Immunity, 13, 715-725. [Google Scholar] [CrossRef] [PubMed]
[3] Glassman, C.R., Mathiharan, Y.K., Jude, K.M., Su, L., Panova, O., Lupardus, P.J., et al. (2021) Structural Basis for IL-12 and IL-23 Receptor Sharing Reveals a Gateway for Shaping Actions on T versus NK Cells. Cell, 184, 983-999.e24. [Google Scholar] [CrossRef] [PubMed]
[4] Parigi, T.L., Iacucci, M. and Ghosh, S. (2022) Blockade of IL-23: What Is in the Pipeline? Journal of Crohn’s and Colitis, 16, ii64-ii72. [Google Scholar] [CrossRef] [PubMed]
[5] Krueger, J.G., Eyerich, K., Kuchroo, V.K., Ritchlin, C.T., Abreu, M.T., Elloso, M.M., et al. (2024) IL-23 Past, Present, and Future: A Roadmap to Advancing IL-23 Science and Therapy. Frontiers in Immunology, 15, Article ID: 1331217. [Google Scholar] [CrossRef] [PubMed]
[6] Abraham, C. and Cho, J.H. (2009) IL-23 and Autoimmunity: New Insights into the Pathogenesis of Inflammatory Bowel Disease. Annual Review of Medicine, 60, 97-110. [Google Scholar] [CrossRef] [PubMed]
[7] Neurath, M.F. (2024) Strategies for Targeting Cytokines in Inflammatory Bowel Disease. Nature Reviews Immunology, 24, 559-576. [Google Scholar] [CrossRef] [PubMed]
[8] Pastras, P., Aggeletopoulou, I., Papantoniou, K. and Triantos, C. (2025) Targeting the IL-23 Receptor Gene: A Promising Approach in Inflammatory Bowel Disease Treatment. International Journal of Molecular Sciences, 26, Article 4775. [Google Scholar] [CrossRef] [PubMed]
[9] Floss, D.M., Moll, J.M. and Scheller, J. (2020) IL-12 and Il-23—Close Relatives with Structural Homologies but Distinct Immunological Functions. Cells, 9, Article 2184. [Google Scholar] [CrossRef] [PubMed]
[10] Schmitt, H., Neurath, M.F. and Atreya, R. (2021) Role of the IL23/IL17 Pathway in Crohn’s Disease. Frontiers in Immunology, 12, Article ID: 622934. [Google Scholar] [CrossRef] [PubMed]
[11] Kamada, N., Hisamatsu, T., Okamoto, S., Chinen, H., Kobayashi, T., Sato, T., et al. (2008) Unique CD14+ Intestinal Macrophages Contribute to the Pathogenesis of Crohn Disease via IL-23/IFN-γ Axis. Journal of Clinical Investigation, 118, 2269-2280. [Google Scholar] [CrossRef] [PubMed]
[12] Łukasik, Z., Gracey, E., Venken, K., Ritchlin, C. and Elewaut, D. (2021) Crossing the Boundaries: IL-23 and Its Role in Linking Inflammation of the Skin, Gut and Joints. Rheumatology, 60, iv16-iv27. [Google Scholar] [CrossRef] [PubMed]
[13] Paul, J., Singh, A.K., Kathania, M., Elviche, T.L., Zeng, M., Basrur, V., et al. (2018) Il-17-Driven Intestinal Fibrosis Is Inhibited by Itch-Mediated Ubiquitination of Hic-5. Mucosal Immunology, 11, 427-436. [Google Scholar] [CrossRef] [PubMed]
[14] Mathur, R., Alam, M.M., Zhao, X., Liao, Y., Shen, J., Morgan, S., et al. (2019) Induction of Autophagy in Cx3cr1+ Mononuclear Cells Limits IL-23/IL-22 Axis-Mediated Intestinal Fibrosis. Mucosal Immunology, 12, 612-623. [Google Scholar] [CrossRef] [PubMed]
[15] Sewell, G.W. and Kaser, A. (2022) Interleukin-23 in the Pathogenesis of Inflammatory Bowel Disease and Implications for Therapeutic Intervention. Journal of Crohn’s and Colitis, 16, ii3-ii19. [Google Scholar] [CrossRef] [PubMed]
[16] Tsukazaki, H. and Kaito, T. (2020) The Role of the IL-23/IL-17 Pathway in the Pathogenesis of Spondyloarthritis. International Journal of Molecular Sciences, 21, Article 6401. [Google Scholar] [CrossRef] [PubMed]
[17] Korta, A., Kula, J. and Gomułka, K. (2023) The Role of IL-23 in the Pathogenesis and Therapy of Inflammatory Bowel Disease. International Journal of Molecular Sciences, 24, Article 10172. [Google Scholar] [CrossRef] [PubMed]
[18] Neurath, M.F. (2019) IL-23 in Inflammatory Bowel Diseases and Colon Cancer. Cytokine & Growth Factor Reviews, 45, 1-8. [Google Scholar] [CrossRef] [PubMed]
[19] Hueber, W., Sands, B.E., Lewitzky, S., Vandemeulebroecke, M., Reinisch, W., Higgins, P.D.R., et al. (2012) Secukinumab, a Human Anti-Il-17a Monoclonal Antibody, for Moderate to Severe Crohn’s Disease: Unexpected Results of a Randomised, Double-Blind Placebo-Controlled Trial. Gut, 61, 1693-1700. [Google Scholar] [CrossRef] [PubMed]
[20] Maxwell, J.R., Zhang, Y., Brown, W.A., Smith, C.L., Byrne, F.R., Fiorino, M., et al. (2015) Differential Roles for Interleukin-23 and Interleukin-17 in Intestinal Immunoregulation. Immunity, 43, 739-750. [Google Scholar] [CrossRef] [PubMed]
[21] Lee, J.S., Tato, C.M., Joyce-Shaikh, B., Gulen, M.F., Cayatte, C., Chen, Y., et al. (2015) Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability. Immunity, 43, 727-738. [Google Scholar] [CrossRef] [PubMed]
[22] Bourgonje, A.R., Ungaro, R.C., Mehandru, S. and Colombel, J. (2025) Targeting the Interleukin 23 Pathway in Inflammatory Bowel Disease. Gastroenterology, 168, 29-52.E3. [Google Scholar] [CrossRef] [PubMed]
[23] Feagan, B.G., Sandborn, W.J., Gasink, C., Jacobstein, D., Lang, Y., Friedman, J.R., et al. (2016) Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease. New England Journal of Medicine, 375, 1946-1960. [Google Scholar] [CrossRef] [PubMed]
[24] Null, K., Chang, H.L., Lissoos, T., Luo, M., Cohen, B., Sands, B.E., et al. (2018) P525 Adherence and Persistence with Vedolizumab among Patients with Inflammatory Bowel Disease in an Academic Medical Centre. Journal of Crohn’s and Colitis, 12, S371-S372. [Google Scholar] [CrossRef] 
[25] Fumery, M., Peyrin-Biroulet, L., Nancey, S., Altwegg, R., Gilletta, C., Veyrard, P., et al. (2021) Effectiveness and Safety of Ustekinumab Intensification at 90 Mg Every 4 Weeks in Crohn’s Disease: A Multicentre Study. Journal of Crohn’s and Colitis, 15, 222-227. [Google Scholar] [CrossRef] [PubMed]
[26] Danese, S., Vermeire, S., D’Haens, G., et al. (2022) Treat to Target Versus Standard of Care for Patients with Crohn’s Disease Treated with Ustekinumab (Stardust): An Open-Label, Multicentre, Randomised Phase 3b Trial. The Lancet Gastroenterology and Hepatology, 7, 294-306.
[27] Allocca, M., Dell’Avalle, C., Zilli, A., Furfaro, F., D’Amico, F., Jairath, V., et al. (2024) Ultrasound Remission after Biologic Induction and Long-Term Endoscopic Remission in Crohn’s Disease: A Prospective Cohort Study. eClinicalMedicine, 71, Article 102559. [Google Scholar] [CrossRef] [PubMed]
[28] Bezzio, C., Bertin, L., Buono, A.D., Privitera, G., Gabbiadini, R., Loy, L., et al. (2025) Revolutionizing Crohn’s Disease Monitoring: The Emerging Role of Intestinal Ultrasound. Current Opinion in Pharmacology, 85, Article 102580. [Google Scholar] [CrossRef] 
[29] Jairath, V., Adsul, S., Allocca, M., Danese, S., Dubinsky, M.C., de Oliveira, M.F., et al. (2025) Integrating Intestinal Ultrasound to Clinical Trials in Patients with Crohn’s Disease: Opportunities and Challenges. Inflammatory Bowel Diseases, 31, 3429-3442. [Google Scholar] [CrossRef] 
[30] Verstockt, B., Salas, A., Sands, B.E., Abraham, C., Leibovitzh, H., Neurath, M.F., et al. (2023) IL-12 and IL-23 Pathway Inhibition in Inflammatory Bowel Disease. Nature Reviews Gastroenterology & Hepatology, 20, 433-446. [Google Scholar] [CrossRef] [PubMed]
[31] Feagan, B.G., Sandborn, W.J., D’Haens, G., Panés, J., Kaser, A., Ferrante, M., et al. (2017) Induction Therapy with the Selective Interleukin-23 Inhibitor Risankizumab in Patients with Moderate-to-Severe Crohn’s Disease: A Randomised, Double-Blind, Placebo-Controlled Phase 2 Study. The Lancet, 389, 1699-1709. [Google Scholar] [CrossRef] [PubMed]
[32] D’Haens, G., Panaccione, R., Baert, F., Bossuyt, P., Colombel, J., Danese, S., et al. (2022) Risankizumab as Induction Therapy for Crohn’s Disease: Results from the Phase 3 Advance and Motivate Induction Trials. The Lancet, 399, 2015-2030. [Google Scholar] [CrossRef] [PubMed]
[33] Dubinsky, M., Ma, C., Griffith, J., Crowell, M., Neimark, E., Kligys, K., et al. (2023) Matching-Adjusted Indirect Comparison between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn’s Disease. Advances in Therapy, 40, 3896-3911. [Google Scholar] [CrossRef] [PubMed]
[34] Ferrante, M., Panaccione, R., Baert, F., Bossuyt, P., Colombel, J., Danese, S., et al. (2022) Risankizumab as Maintenance Therapy for Moderately to Severely Active Crohn’s Disease: Results from the Multicentre, Randomised, Double-Blind, Placebo-Controlled, Withdrawal Phase 3 Fortify Maintenance Trial. The Lancet, 399, 2031-2046. [Google Scholar] [CrossRef] [PubMed]
[35] Zinger, A., Choi, D., Choi, N., Cohen, R.D. and Rubin, D.T. (2024) Risankizumab Effectiveness and Safety in Crohn’s Disease: Real-World Data from a Large Tertiary Center. Clinical Gastroenterology and Hepatology, 22, 1336-1338.E2. [Google Scholar] [CrossRef] [PubMed]
[36] Peyrin-Biroulet, L., Chapman, J.C., Colombel, J., Caprioli, F., D’Haens, G., Ferrante, M., et al. (2024) Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease. New England Journal of Medicine, 391, 213-223. [Google Scholar] [CrossRef] [PubMed]
[37] Sandborn, W.J., D’Haens, G.R., Reinisch, W., Panés, J., Chan, D., Gonzalez, S., et al. (2022) Guselkumab for the Treatment of Crohn’s Disease: Induction Results from the Phase 2 GALAXI-1 Study. Gastroenterology, 162, 1650-1664.E8. [Google Scholar] [CrossRef] [PubMed]
[38] Danese, S., Panaccione, R., Feagan, B.G., et al. (2024) Efficacy and Safety of 48 Weeks of Guselkumab for Patients with Crohn’s Disease: Maintenance Results from the Phase 2, Randomised, Double-Blind Galaxi-1 Trial. The Lancet Gastroenterology and Hepatology, 9, 133-146.
[39] Hart, A., Panaccione, R., Steinwurz, F., Danese, S., Hisamatsu, T., Cao, Q., et al. (2025) Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants with Moderately to Severely Active Crohn’s Disease: Results from the Phase 3 GRAVITI Study. Gastroenterology, 169, 308-325. [Google Scholar] [CrossRef] [PubMed]
[40] Panaccione, R., Feagan, B.G., Afzali, A., Rubin, D.T., Reinisch, W., Panés, J., et al. (2025) Efficacy and Safety of Intravenous Induction and Subcutaneous Maintenance Therapy with Guselkumab for Patients with Crohn’s Disease (GALAXI-2 and GALAXI-3): 48-Week Results from Two Phase 3, Randomised, Placebo and Active Comparator-Controlled, Double-Blind, Triple-Dummy Trials. The Lancet, 406, 358-375. [Google Scholar] [CrossRef] [PubMed]
[41] Sands, B.E., Peyrin-Biroulet, L., Kierkus, J., Higgins, P.D.R., Fischer, M., Jairath, V., et al. (2022) Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients with Crohn’s Disease. Gastroenterology, 162, 495-508. [Google Scholar] [CrossRef] [PubMed]
[42] Ferrante, M., D’Haens, G., Jairath, V., Danese, S., Chen, M., Ghosh, S., et al. (2024) Efficacy and Safety of Mirikizumab in Patients with Moderately-to-Severely Active Crohn’s Disease: A Phase 3, Multicentre, Randomised, Double-Blind, Placebo-Controlled and Active-Controlled, Treat-Through Study. The Lancet, 404, 2423-2436. [Google Scholar] [CrossRef] [PubMed]
[43] Sands, B.E., Chen, J., Feagan, B.G., Penney, M., Rees, W.A., Danese, S., et al. (2017) Efficacy and Safety of MEDI2070, an Antibody against Interleukin 23, in Patients with Moderate to Severe Crohn’s Disease: A Phase 2a Study. Gastroenterology, 153, 77-86.E6. [Google Scholar] [CrossRef] [PubMed]
[44] Zhu, X., Fang, X., Wang, Q., Li, M., Zhang, K., Xie, L., et al. (2025) Short-Term Effectiveness of Ustekinumab in Crohn’s Disease: Results from a Real-World Retrospective Multicenter Study in China. International Journal of General Medicine, 18, 2589-2597. [Google Scholar] [CrossRef] [PubMed]
[45] Sandborn, W.J., Feagan, B.G., Danese, S., O’Brien, C.D., Ott, E., Marano, C., et al. (2021) Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies. Inflammatory Bowel Diseases, 27, 994-1007. [Google Scholar] [CrossRef] [PubMed]
[46] Cheng, D., Kochar, B.D., Cai, T. and Ananthakrishnan, A.N. (2022) Risk of Infections with Ustekinumab and Tofacitinib Compared to Tumor Necrosis Factor Α Antagonists in Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 20, 2366-2372.e6. [Google Scholar] [CrossRef] [PubMed]
[47] Cheng, D., Kochar, B., Cai, T., Ritchie, C.S. and Ananthakrishnan, A.N. (2022) Comorbidity Influences the Comparative Safety of Biologic Therapy in Older Adults with Inflammatory Bowel Diseases. American Journal of Gastroenterology, 117, 1845-1850. [Google Scholar] [CrossRef] [PubMed]
[48] Ferrante, M., Feagan, B.G., Panés, J., Baert, F., Louis, E., Dewit, O., et al. (2021) Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn’s Disease: Results from the Phase 2 Open-Label Extension Study. Journal of Crohn’s and Colitis, 15, 2001-2010. [Google Scholar] [CrossRef] [PubMed]
[49] Peyrin-Biroulet, L., Atreya, R., Danese, S., Lindsay, J.O., Chapman, J.C., Anschutz, T., et al. (2025) Efficacy and Safety of Risankizumab in Patients with Moderately to Severely Active Crohn’s Disease: Interim Results from the Sequence Open-Label Extension Study. Journal of Crohn’s and Colitis, 19, F213. [Google Scholar] [CrossRef] 

为你推荐